Genpact Stock Plummets to New 52-Week Low at $33.54

Genpact has reached a new 52-week low, trading at USD 33.54 as of April 29, 2026. This marks a significant decline for the small-cap company, which operates within the miscellaneous industry and has a market capitalization of USD 6,540 million. Over the past year, Genpact's performance has been modest, with a return of 3.04%, significantly lagging behind the S&P 500's 28.33% gain. Despite the recent price drop, Genpact maintains a relatively low price-to-earnings (P/E) ratio of 12.00, indicating a potentially attractive valuation compared to its peers. The company boasts a strong return on equity of 22.31% and a low debt-to-equity ratio of 0.15, reflecting solid financial health. Additionally, Genpact has demonstrated management efficiency, with a return on capital employed (ROCE) of 19.50%. The stock's 52-week high was recorded at USD 50.41, highlighting the volatility in its price over the past year. While the company has faced challenges, it continues to show healthy long-term growth potential, with operating profit increasing at an annual rate of 10.73%.